MarketCap
Facebook
X
Telegram
OncoSec Medical Incorporated Balance Sheet 2022-2008 | ONCS
Brief overview of OncoSec Medical Incorporated's financial position
The review uses the five latest available annual reports between 2018 and 2022.
Assets fell from $30.2 million to $21.9 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities expanded faster than the asset base, +115.2% versus -27.7%. Debt-service capacity deserves attention.
Equity finances 28% of the balance sheet, compared with 75.8% at the start. The cushion remains adequate.
Net debt moved below zero to -$4.7 million, reflecting surplus cash over debt.
The cash reserve occupies 30.6% of the balance sheet, previously 12.6%. It is one marker of short-term resilience.
The accumulated result is -$286 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
What the balance sheet shows
OncoSec Medical Incorporated's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet OncoSec Medical Incorporated
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-4.65 M | -43.9 M | -18.4 M | -25.1 M | -3.8 M | -11.4 M | -28.7 M | -32 M | -37.9 M | -4.97 M | -5.14 M | -2.46 M | - | - | - |
Long Term Debt |
937 K | 1.23 M | 1.45 M | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.11 M | 845 K | 500 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 6.35 M | 636 K | 1.47 M | 1.14 M | 887 K | - | - | - | 979 K | 1.5 M | - | - | - |
Total Current Liabilities |
6.63 M | 7.96 M | 9.68 M | 4.98 M | 5.85 M | 3.4 M | 3.47 M | 2.86 M | 1.32 M | 1.77 M | 2.02 M | 6.54 M | - | - | - |
Total Liabilities |
15.8 M | 18.2 M | 16 M | 5.61 M | 7.32 M | 4.54 M | 4.35 M | 2.89 M | 1.32 M | 1.77 M | 3 M | 8.04 M | - | - | - |
Retained Earnings |
-286 M | -252 M | -207 M | -164 M | -134 M | -94.9 M | -73.5 M | -46.6 M | -25.4 M | -13.4 M | -6.2 M | -3.84 M | - | - | - |
Total Assets |
21.9 M | 56.3 M | 29.9 M | 29.9 M | 30.2 M | 15.2 M | 32.4 M | 35.6 M | 39.4 M | 6.51 M | 7.43 M | 5.67 M | - | - | - |
Cash and Cash Equivalents |
6.7 M | 46 M | 20.4 M | 25.1 M | 3.8 M | 11.4 M | 28.7 M | 32 M | 37.9 M | 4.97 M | 5.14 M | 2.46 M | 237 | - | - |
Book Value |
6.12 M | 38.1 M | 13.9 M | 24.3 M | 22.9 M | 10.7 M | 28.1 M | 32.7 M | 38.1 M | 4.74 M | 4.43 M | -2.36 M | - | - | - |
Total Shareholders Equity |
6.12 M | 38.1 M | 13.9 M | 24.3 M | 22.9 M | 10.7 M | 28.1 M | 32.7 M | 38.1 M | 4.74 M | 4.43 M | -2.36 M | -30.1 K | 6.1 K | 39.8 K |
All numbers in USD currency
Quarterly Balance Sheet OncoSec Medical Incorporated
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
214 K | 3.51 M | 4.7 M | 4.42 M | 4.7 M | 4.98 M | 1.12 M | 5.49 M | 1.12 M | 1.29 M | 6.13 M | 6.07 M | 6.13 M | 558 K | - | 558 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
14.4 M | 15.4 M | 15.3 M | 14.1 M | 15.3 M | 16.8 M | 21.9 M | 16.2 M | 21.9 M | 17.7 M | 16.6 M | 17.4 M | 16.6 M | 7.95 M | 7.56 M | 5.82 M | 7.56 M | 6.98 M | 4.09 M | 4.36 M | 4.09 M | 5.16 M | 4.61 M | 4.01 M | 4.61 M | 4.45 M | 4.34 M | 4.28 M | 4.34 M | 3.18 M | 1.51 M | 1.76 M | 1.51 M | 2.89 M | 896 K | 1.18 M | 896 K | 1.85 M | 2.69 M | 2.5 M | 2.69 M | 2.83 M | 5.02 M | 3 M | 5.02 M | 3.56 M | - | 3.56 M | 8.04 M | 8.04 M |
Retained Earnings |
-301 M | -294 M | -271 M | -278 M | -271 M | -262 M | -231 M | -240 M | -231 M | -220 M | -188 M | -198 M | -188 M | -174 M | -150 M | -157 M | -150 M | -142 M | -112 M | -122 M | -112 M | -101 M | -84.5 M | -89 M | -84.5 M | -79.1 M | -60.7 M | -66.9 M | -60.7 M | -53.6 M | -34 M | -40 M | -34 M | -29.4 M | -18 M | -21.8 M | -18 M | -15.4 M | -9.85 M | -11.6 M | -9.85 M | -8.23 M | -3.8 M | -4.61 M | -3.8 M | -1.12 M | - | -1.12 M | -3.84 M | -3.84 M |
Total Assets |
8.87 M | 14.4 M | 35.1 M | 28 M | 35.1 M | 45.6 M | 70 M | 63.6 M | 70 M | 33.9 M | 19.8 M | 39.1 M | 19.8 M | 23.2 M | 32.2 M | 27 M | 32.2 M | 32.2 M | 22.1 M | 37.1 M | 22.1 M | 18.7 M | 24.3 M | 20 M | 24.3 M | 28.1 M | 32.9 M | 28.3 M | 32.9 M | 30.4 M | 32.7 M | 27.6 M | 32.7 M | 35.7 M | 19.8 M | 25.7 M | 19.8 M | 17.1 M | 10.7 M | 8.87 M | 10.7 M | 5.52 M | 2.98 M | 8.81 M | 2.98 M | 4.14 M | - | 4.14 M | 5.67 M | 5.67 M |
Cash and Cash Equivalents |
3.68 M | 8.1 M | 25.2 M | 17.3 M | 22.1 M | 35.7 M | 60.3 M | 54.4 M | 60.3 M | 24 M | 9.26 M | 30.1 M | 9.26 M | 16.9 M | 24.5 M | 22.3 M | 24.5 M | 19 M | 17.9 M | 10.1 M | 17.9 M | 21.4 M | 20.5 M | 16.1 M | 20.5 M | 24.4 M | 28.8 M | 24 M | 28.8 M | 26.9 M | 30.7 M | 25.4 M | 30.7 M | 34 M | 18.5 M | 24.3 M | 18.5 M | 15.2 M | 8.98 M | 7.33 M | 8.98 M | 3.53 M | 456 K | 6.57 M | 456 K | 1.41 M | 3.69 K | 1.41 M | 2.46 M | 1.41 M |
Book Value |
-5.49 M | -984 K | 19.8 M | 13.9 M | 19.8 M | 28.8 M | 48.1 M | 47.4 M | 48.1 M | 16.2 M | 3.17 M | 21.7 M | 3.17 M | 15.3 M | 24.7 M | 21.2 M | 24.7 M | 25.2 M | 18 M | 32.7 M | 18 M | 13.5 M | 19.7 M | 16 M | 19.7 M | 23.6 M | 28.6 M | 24 M | 28.6 M | 27.2 M | 31.2 M | 25.9 M | 31.2 M | 32.8 M | 18.9 M | 24.5 M | 18.9 M | 15.2 M | 8.02 M | 6.38 M | 8.02 M | 2.69 M | -2.04 M | 5.81 M | -2.04 M | 581 K | - | 581 K | -2.36 M | -2.36 M |
Total Shareholders Equity |
-5.49 M | -984 K | 19.8 M | 13.9 M | 19.8 M | 28.8 M | 48.1 M | 47.4 M | 48.1 M | 16.2 M | 3.17 M | 21.7 M | 3.17 M | 15.3 M | 24.7 M | 21.2 M | 24.7 M | 25.2 M | 18 M | 32.7 M | 18 M | 13.5 M | 19.7 M | 16 M | 19.7 M | 23.6 M | 28.6 M | 24 M | 28.6 M | 27.2 M | 31.2 M | 25.9 M | 31.2 M | 34.6 M | 18.9 M | 24.5 M | 18.9 M | 15.2 M | 8.02 M | 6.38 M | 8.02 M | 2.69 M | -2.04 M | 5.81 M | -2.04 M | 581 K | - | 581 K | -2.36 M | -2.36 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of OncoSec Medical Incorporated, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada